Scancell Holdings () has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly.
CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing antibody technology.
News here too on what is unique about Scancell's antibody pipeline.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE